Myocardial repair: from salvage to tissue reconstruction

References

• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), e25–e146 (2007).
   PubMed Web of Science ®Google Scholar
• Jessup M, Brozena S. Heart failure. N. Engl. J. Med.348, 2007–2018 (2003).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. Rev. Cardiovasc. Med.4(Suppl. 3), S3–S12 (2003).
   PubMedGoogle Scholar
• Boersma E, Mercado N, Poldermans D et al. Acute myocardial infarction. Lancet361(9360), 847–858 (2003).
   PubMed Web of Science ®Google Scholar
• Abbate A, Bussani R, Amin MS, Vetrovec GW, Baldi A. Acute myocardial infarction and heart failure: role of apoptosis. Int. J. Biochem. Cell. Biol.38(11), 1834–1840 (2006).
   PubMed Web of Science ®Google Scholar
• Garg S, Narula J, Chandrashekhar Y. Apoptosis and heart failure: clinical relevance and therapeutic target. J. Mol. Cell. Cardiol.38(1), 73–79 (2005).
   PubMed Web of Science ®Google Scholar
• Wencker D, Chandra M, Nguyen K et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest.111(10), 1497–1504 (2003).
   PubMed Web of Science ®Google Scholar
• Mani K, Kitsis RN. Myocyte apoptosis: programming ventricular remodeling. J. Am. Coll. Cardiol.41(5), 761–764 (2003).
   PubMed Web of Science ®Google Scholar
• O’Neill BT, Abel ED. Akt1 in the cardiovascular system: friend or foe? J. Clin. Invest.115(8), 2059–2064 (2005).
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc. Res.53(1), 31–47 (2002).
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid. Redox Signal.8(11–12), 1907–1939 (2006).
   PubMed Web of Science ®Google Scholar
• Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res.94(12), 1543–1553 (2004).
   PubMed Web of Science ®Google Scholar
• Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med.13(8), 952–961 (2007).
   PubMed Web of Science ®Google Scholar
• Bujak M, Ren G, Kweon HJ et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation116(19), 2127–2138 (2007).
   PubMed Web of Science ®Google Scholar
• Leask A. TGFβ, cardiac fibroblasts, and the fibrotic response. Cardiovasc. Res.74(2), 207–212 (2007).
   PubMed Web of Science ®Google Scholar
• Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res.69(3), 604–613 (2006).
   PubMed Web of Science ®Google Scholar
• Tomanek RJ, Zheng W, Yue X. Growth factor activation in myocardial vascularization: therapeutic implications. Mol. Cell. Biochem.264(1–2), 3–11 (2004).
   PubMed Web of Science ®Google Scholar
• Szmitko PE, Fedak PW, Weisel RD et al. Endothelial progenitor cells: new hope for a broken heart. Circulation107(24), 3093–3100 (2003).
   PubMed Web of Science ®Google Scholar
• Renault MA, Losordo DW. Therapeutic myocardial angiogenesis. Microvasc. Res.74(2–3), 159–171 (2007).
   PubMed Web of Science ®Google Scholar
• Garry DJ, Olson EN. A common progenitor at the heart of development. Cell127(6), 1101–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Germani A, Di Rocco G, Limana F, Martelli F, Capogrossi MC. Molecular mechanisms of cardiomyocyte regeneration and therapeutic outlook. Trends Mol. Med.13(3), 125–133 (2007).
   PubMed Web of Science ®Google Scholar
• Leri A, Kajstura J, Anversa P, Frishman WH. Myocardial regeneration and stem cell repair. Curr. Probl. Cardiol.33(3), 91–153 (2008).
   PubMed Web of Science ®Google Scholar
• Ellison GM, Torella D, Karakikes I, Nadal-Ginard B. Myocyte death and renewal: modern concepts of cardiac cellular homeostasis. Nat. Clin. Pract. Cardiovasc. Med.4(Suppl. 1), S52–S59 (2007).
   Google Scholar
• Wu SM, Chien KR, Mummery C. Origins and fates of cardiovascular progenitor cells. Cell132(4), 537–543 (2008).
   PubMed Web of Science ®Google Scholar
• Hsieh PC, Segers VF, Davis ME et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat. Med.13(8), 970–974 (2007).
   PubMed Web of Science ®Google Scholar
• Bicknell KA, Coxon CH, Brooks G. Can the cardiomyocyte cell cycle be reprogrammed? J. Mol. Cell. Cardiol.42(4), 706–721 (2007).
   PubMed Web of Science ®Google Scholar
• Regula KM, Rzeszutek MJ, Baetz D, Seneviratne C, Kirshenbaum LA. Therapeutic opportunities for cell cycle re-entry and cardiac regeneration. Cardiovasc. Res.64(3), 395–401 (2004).
   PubMed Web of Science ®Google Scholar
• Costa AD. Divide to survive: myocardial regeneration and functional recovery after cell cycle activation in injured hearts. Cardiovasc. Res.78(1), 1–2 (2008).
   PubMed Web of Science ®Google Scholar
• Sussman M. “AKT”ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation. Trends Cardiovasc. Med.17(7), 235–240 (2007).
   PubMed Web of Science ®Google Scholar
• Collins SD, Baffour R, Waksman R. Cell therapy in myocardial infarction. Cardiovasc. Revasc. Med.8(1), 43–51 (2007).
   PubMedGoogle Scholar
• Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler. Thromb. Vasc. Biol.28(2), 208–216 (2008).
   PubMed Web of Science ®Google Scholar
• Laflamme MA, Zbinden S, Epstein SE, Murry CE. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu. Rev. Pathol.2, 307–339 (2007).
   PubMed Web of Science ®Google Scholar
• Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature451(7181), 937–942 (2008).
   PubMed Web of Science ®Google Scholar
• Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest.103(5), 697–705 (1999).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature410(6829), 701–705 (2001).
   PubMed Web of Science ®Google Scholar
• Balsam LB, Wagers AJ, Christensen JL et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature428(6983), 668–673 (2004).
   PubMed Web of Science ®Google Scholar
• Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature428(6983), 664–668 (2004).
   PubMed Web of Science ®Google Scholar
• Rota M, Kajstura J, Hosoda T et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc. Natl Acad. Sci. USA104(45), 17783–17788 (2007).
   PubMed Web of Science ®Google Scholar
• Anversa P, Leri A, Rota M et al. Concise review: stem cells, myocardial regeneration, and methodological artifacts. Stem Cells25(3), 589–601 (2007).
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science284(5411), 143–147 (1999).
   PubMed Web of Science ®Google Scholar
• Minguell JJ, Erices A. Mesenchymal stem cells and the treatment of cardiac disease. Exp. Biol. Med. (Maywood)231(1), 39–49 (2006).
   PubMed Web of Science ®Google Scholar
• Dai W, Hale SL, Kloner RA. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen. Med.2(1), 63–68 (2007).
   PubMed Web of Science ®Google Scholar
• Gnecchi M, He H, Noiseux N et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J.20(6), 661–669 (2006).
   PubMed Web of Science ®Google Scholar
• Noiseux N, Gnecchi M, Lopez-Ilasaca M et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther.14(6), 840–850 (2006).
   PubMed Web of Science ®Google Scholar
• Miyahara Y, Nagaya N, Kataoka M et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat. Med.12(4), 459–465 (2006).
   PubMed Web of Science ®Google Scholar
• Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation103(23), 2776–2779 (2001).
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science275(5302), 964–967 (1997).
   PubMed Web of Science ®Google Scholar
• Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation106(24), 3009–3017 (2002).
   PubMed Web of Science ®Google Scholar
• Ii M, Nishimura H, Iwakura A et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported” nitric oxide synthase activity. Circulation111(9), 1114–1120 (2005).
   PubMed Web of Science ®Google Scholar
• Sohn RL, Jain M, Liao R. Adult stem cells and heart regeneration. Expert Rev. Cardiovasc. Ther.5(3), 507–517 (2007).
   PubMedGoogle Scholar
• Britten MB, Abolmaali ND, Assmus B et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation108(18), 2212–2218 (2003).
   PubMed Web of Science ®Google Scholar
• Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J. Am. Coll. Cardiol.44(8), 1690–1699 (2004).
   PubMed Web of Science ®Google Scholar
• Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1199–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1210–1221 (2006).
   PubMed Web of Science ®Google Scholar
• Lipinski MJ, Biondi-Zoccai GG, Abbate A et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J. Am. Coll. Cardiol.50(18), 1761–1767 (2007).
   PubMed Web of Science ®Google Scholar
• Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ. Res.87(5), 378–384 (2000).
   PubMed Web of Science ®Google Scholar
• Rehman J, Li J, Orschell CM, March KL. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation107(8), 1164–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Dewald O, Zymek P, Winkelmann K et al. CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res.96(8), 881–889 (2005).
   PubMed Web of Science ®Google Scholar
• Minatoguchi S, Takemura G, Chen XH et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation109(21), 2572–2580 (2004).
   PubMed Web of Science ®Google Scholar
• van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am. J. Pathol.170(3), 818–829 (2007).
   PubMed Web of Science ®Google Scholar
• Nahrendorf M, Swirski FK, Aikawa E et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med.204(12), 3037–3047 (2007).
   PubMed Web of Science ®Google Scholar
• Leor J, Rozen L, Zuloff-Shani A et al.Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation114(1 Suppl.), I94–I100 (2006).
   PubMed Web of Science ®Google Scholar
• Steendijk P, Smits PC, Valgimigli M et al. Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure-volume loops. Nat. Clin. Pract. Cardiovasc. Med.3(Suppl. 1), S94–S100 (2006).
   PubMedGoogle Scholar
• Tambara K, Sakakibara Y, Sakaguchi G et al. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation108(Suppl. 1), II259–II263 (2003).
   PubMed Web of Science ®Google Scholar
• Pagani FD, DerSimonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol.41(5), 879–888 (2003).
   PubMed Web of Science ®Google Scholar
• Hagege AA, Carrion C, Menasche P et al. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet361(9356), 491–492 (2003).
   PubMed Web of Science ®Google Scholar
• Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. First randomized placebo-controlled study of myoblast transplantation. Circulation117(9), 1189–1200(2008).
   PubMed Web of Science ®Google Scholar
• Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res.95(9), 911–921 (2004).
   PubMed Web of Science ®Google Scholar
• Linke A, Muller P, Nurzynska D et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc. Natl Acad. Sci. USA102(25), 8966–8971 (2005).
   PubMed Web of Science ®Google Scholar
• Urbanek K, Rota M, Cascapera S et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res.97(7), 663–673 (2005).
   PubMed Web of Science ®Google Scholar
• Urbanek K, Torella D, Sheikh F et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc. Natl Acad. Sci. USA102(24), 8692–8697 (2005).
   PubMed Web of Science ®Google Scholar
• Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl Acad. Sci. USA100(21), 12313–12318 (2003).
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell114(6), 763–776 (2003).
   PubMed Web of Science ®Google Scholar
• Laugwitz KL, Moretti A, Lam J et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature433(7026), 647–653 (2005).
   PubMed Web of Science ®Google Scholar
• Caspi O, Huber I, Kehat I et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J. Am. Coll. Cardiol.50(19), 1884–1893 (2007).
   PubMed Web of Science ®Google Scholar
• Leor J, Gerecht S, Cohen S et al. Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart93(10), 1278–1284 (2007).
   PubMed Web of Science ®Google Scholar
• Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol.25(9), 1015–1024 (2007).
   PubMed Web of Science ®Google Scholar
• Maulik N, Thirunavukkarasu M. Growth factor/s and cell therapy in myocardial regeneration. J. Mol. Cell. Cardiol.44(2), 219–227 (2007).
   PubMed Web of Science ®Google Scholar
• Vandervelde S, Van Luyn MJA, Tio RA, Harmsen MC. Signaling factors in stem cell-mediated repair of infarcted myocardium. J. Mol. Cell. Cardiol.39, 363–376 (2005).
   PubMed Web of Science ®Google Scholar
• Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation109(21), 2487–2491 (2004).
   PubMed Web of Science ®Google Scholar
• Zohlnhofer D, Dibra A, Koppara T et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol.51(15), 1429–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Isner JM. Myocardial gene therapy. Nature415(6868), 234–239 (2002).
   PubMed Web of Science ®Google Scholar
• Lyon AR, Sato M, Hajjar RJ, Samulski RJ, Harding SE. Gene therapy: targeting the myocardium. Heart94(1), 89–99 (2008).
   PubMed Web of Science ®Google Scholar
• Gaffney MM, Hynes SO, Barry F, O’Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br. J. Pharmacol.152(2), 175–188 (2007).
   PubMed Web of Science ®Google Scholar
• Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol. Ther.15(7), 1233–1247 (2007).
   PubMed Web of Science ®Google Scholar
• Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc. Res.73(3), 453–462 (2007).
   PubMed Web of Science ®Google Scholar
• Kondo I, Ohmori K, Oshita A et al. Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: the first demonstration of myocardial transfer of a “functional” gene using ultrasonic microbubble destruction. J. Am. Coll. Cardiol.44(3), 644–653 (2004).
   PubMed Web of Science ®Google Scholar
• Crottogini A, Meckert PC, Vera Janavel G et al. Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum. Gene Ther.14(14), 1307–1318 (2003).
   PubMed Web of Science ®Google Scholar
• Ruixing Y, Dezhai Y, Hai W et al. Intramyocardial injection of vascular endothelial growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis. Eur. J. Heart Fail.9(4), 343–351 (2007).
   PubMed Web of Science ®Google Scholar
• Hao X, Mansson-Broberg A, Grinnemo KH et al. Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc. Res.73(3), 481–487 (2007).
   PubMed Web of Science ®Google Scholar
• Vera Janavel G, Crottogini A, Cabeza Meckert P et al. Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. Gene Ther.13(15), 1133–1142 (2006).
   PubMed Web of Science ®Google Scholar
• Ripa RS, Wang Y, Jorgensen E et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J.27(15), 1785–1792 (2006).
   PubMed Web of Science ®Google Scholar
• Kastrup J, Jorgensen E, Ruck A et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol.45(7), 982–988 (2005).
   PubMed Web of Science ®Google Scholar
• Williams ML, Koch WJ. Viral-based myocardial gene therapy approaches to alter cardiac function. Annu. Rev. Physiol.66, 49–75 (2004).
   PubMed Web of Science ®Google Scholar
• Belke DD, Gloss B, Hollander JM et al.In vivo gene delivery of HSP70i by adenovirus and adeno-associated virus preserves contractile function in mouse heart following ischemia–reperfusion. Am. J. Physiol. Heart Circ. Physiol.291(6), H2905–H2910 (2006).
   Google Scholar
• Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am. J. Physiol. Regul. Integr. Comp. Physiol.293(2), R568–R577 (2007).
   PubMed Web of Science ®Google Scholar
• Pleger ST, Boucher M, Most P, Koch WJ. Targeting myocardial β-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J. Card. Fail.13(5), 401–414 (2007).
   PubMed Web of Science ®Google Scholar
• Pleger ST, Remppis A, Heidt B et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol. Ther.12(6), 1120–1129 (2005).
   PubMed Web of Science ®Google Scholar
• Most P, Pleger ST, Volkers M et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J. Clin. Invest.114(11), 1550–1563 (2004).
   PubMed Web of Science ®Google Scholar
• Kaye DM, Preovolos A, Marshall T et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J. Am. Coll. Cardiol.50(3), 253–260 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Hilton JD, Arnold JM et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a Phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther.13(21), 1503–1511 (2006).
   PubMed Web of Science ®Google Scholar
• Palomeque J, Chemaly ER, Colosi P et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther.14(13), 989–997 (2007).
   PubMed Web of Science ®Google Scholar
• Su H, Joho S, Huang Y et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc. Natl Acad. Sci. USA101(46), 16280–16285 (2004).
   PubMed Web of Science ®Google Scholar
• Agrawal RS, Muangman S, Layne MD et al. Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. Gene Ther.11(12), 962–969 (2004).
   PubMed Web of Science ®Google Scholar
• Loor G, Schumacker PT. Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ.15(4), 686–690(2008).
   PubMed Web of Science ®Google Scholar
• Pachori AS, Melo LG, Zhang L, Solomon SD, Dzau VJ. Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery. J. Am. Coll. Cardiol.47(3), 635–643 (2006).
   PubMed Web of Science ®Google Scholar
• Liu X, Simpson JA, Brunt KR et al. Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am. J. Physiol. Heart Circ. Physiol.293(1), H48–H59 (2007).
   PubMed Web of Science ®Google Scholar
• Pleger ST, Most P, Boucher M et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation115(19), 2506–2515 (2007).
   PubMed Web of Science ®Google Scholar
• Staudacher DL, Flugelman MY. Cell and gene therapies in cardiovascular disease with special focus on the no option patient. Curr. Gene Ther.6(6), 609–623 (2006).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Gnecchi M, Pachori AS. Enhancing stem cell therapy through genetic modification. J. Am. Coll. Cardiol.46(7), 1351–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Melo LG, Pachori AS, Kong D et al. Gene and cell-based therapies for heart disease. FASEB J.18(6), 648–663 (2004).
   PubMed Web of Science ®Google Scholar
• Haider HK, Elmadbouh I, Jean-Baptiste M, Ashraf M. Nonviral vector gene modification of stem cells for myocardial repair. Mol. Med.14(1–2), 79–86 (2008).
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Omura T, Yoshiyama M et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol.25(6), 1168–1173 (2005).
   PubMed Web of Science ®Google Scholar
• Yang J, Zhou W, Zheng W et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology107(1), 17–29 (2007).
   PubMed Web of Science ®Google Scholar
• Li W, Ma N, Ong LL et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells25(8), 2118–2127 (2007).
   PubMed Web of Science ®Google Scholar
• Tang YL, Tang Y, Zhang YC et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol.46(7), 1339–1350 (2005).
   PubMed Web of Science ®Google Scholar
• Mangi AA, Noiseux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med.9(9), 1195–1201 (2003).
   PubMed Web of Science ®Google Scholar
• Mirotsou M, Zhang Z, Deb A et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc. Natl Acad. Sci. USA104(5), 1643–1648 (2007).
   PubMed Web of Science ®Google Scholar
• DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp. Cell Res.298(1), 167–177 (2004).
   PubMed Web of Science ®Google Scholar
• Jiang S, Haider HK, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ. Res.99(7), 776–784 (2006).
   PubMed Web of Science ®Google Scholar
• Shujia J, Haider HK, Idris NM, Lu G, Ashraf M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc. Res.77(3), 525–533 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng Z, Ou L, Zhou X et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther.16(3), 571–579 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang D, Fan GC, Zhou X et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J. Mol. Cell. Cardiol.44(2), 281–292 (2007).
   PubMed Web of Science ®Google Scholar
• Yau TM, Kim C, Li G et al. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation112(9 Suppl.), I-123–I-128 (2005).
   Google Scholar
• Spiegelstein D, Kim C, Zhang Y et al. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. Am. J. Physiol. Heart Circ. Physiol.293(6), H3311–H3316 (2007).
   Google Scholar
• Payne TR, Oshima H, Okada M et al. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J. Am. Coll. Cardiol.50(17), 1677–1684 (2007).
   PubMed Web of Science ®Google Scholar
• Roell W, Lewalter T, Sasse P et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature450(7171), 819–824 (2007).
   PubMed Web of Science ®Google Scholar
• Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 – an update. J. Gene Med.9(10), 833–842 (2007).
   PubMed Web of Science ®Google Scholar
• Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J. Am. Coll. Cardiol.48(5), 907–913 (2006).
   PubMed Web of Science ®Google Scholar
• Radisic M, Park H, Gerecht S et al. Biomimetic approach to cardiac tissue engineering. Philos. Trans. R Soc. Lond. B Biol. Sci.362(1484), 1357–1368 (2007).
   PubMed Web of Science ®Google Scholar
• Leor J, Landa N, Cohen S. Renovation of the injured heart with myocardial tissue engineering. Expert Rev. Cardiovasc. Ther.4(2), 1–14 (2006).
   PubMedGoogle Scholar
• Davis ME, Hsieh PC, Grodzinsky AJ, Lee RT. Custom design of the cardiac microenvironment with biomaterials. Circ. Res.97(1), 8–15 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmermann WH, Didie M, Doker S et al. Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc. Res.71(3), 419–429 (2006).
   PubMed Web of Science ®Google Scholar
• Giraud MN, Armbruster C, Carrel T, Tevaearai HT. Current state of the art in myocardial tissue engineering. Tissue Eng.13(8), 1825–1836 (2007).
   PubMedGoogle Scholar
• Eschenhagen T, Fink C, Remmers U et al. Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J.11(8), 683–694 (1997).
   PubMed Web of Science ®Google Scholar
• Zimmermann WH, Schneiderbanger K, Schubert P et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res.90(2), 223–230 (2002).
   PubMed Web of Science ®Google Scholar
• Zimmermann WH, Melnychenko I, Wasmeier G et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med.12(4), 452–458 (2006).
   PubMed Web of Science ®Google Scholar
• Kofidis T, Lenz A, Boublik J et al. Pulsatile perfusion and cardiomyocyte viability in a solid three-dimensional matrix. Biomaterials24(27), 5009–5014 (2003).
   PubMed Web of Science ®Google Scholar
• Leor J, Aboulafia-Etzion S, Dar A et al. Bioengineered cardiac grafts. A new approach to repair the infarcted myocardium? Circulation102(Suppl. II), 56–61 (2000).
   Web of Science ®Google Scholar
• Shachar M, Cohen S. Cardiac tissue engineering, ex-vivo: design principles in biomaterials and bioreactors. Heart Fail. Rev.8(3), 271–276 (2003).
   PubMed Web of Science ®Google Scholar
• Radisic M, Park H, Shing H et al. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc. Natl Acad. Sci. USA101(52), 18129–18134 (2004).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Yamato M, Isoi Y et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ. Res.90(3), e40 (2002).
   PubMed Web of Science ®Google Scholar
• Furuta A, Miyoshi S, Itabashi Y et al. Pulsatile cardiac tissue grafts using a novel three-dimensional cell sheet manipulation technique functionally integrates with the host heart, in vivo. Circ. Res.98(5), 705–712 (2006).
   PubMed Web of Science ®Google Scholar
• McDevitt TC, Woodhouse KA, Hauschka SD, Murry CE, Stayton PS. Spatially organized layers of cardiomyocytes on biodegradable polyurethane films for myocardial repair. J. Biomed. Mater. Res. A66(3), 586–595 (2003).
   PubMed Web of Science ®Google Scholar
• Carrier RL, Rupnick M, Langer R et al. Perfusion improves tissue architecture of engineered cardiac muscle. Tissue Eng.8(2), 175–188 (2002).
   PubMedGoogle Scholar
• Radisic M, Yang L, Boublik J et al. Medium perfusion enables engineering of compact and contractile cardiac tissue. Am. J. Physiol. Heart Circ. Physiol.286(2), H507–H516 (2004).
   PubMed Web of Science ®Google Scholar
• Dvir T, Benishti N, Shachar M, Cohen S. A novel perfusion bioreactor providing a homogenous milieu for tissue regeneration. Tissue Eng.12, 2843–2852 (2006).
   PubMedGoogle Scholar
• Dvir T, Levy O, Shachar M, Granot Y, Cohen S. Activation of the ERK1/2 cascade via pulsatile interstitial fluid flow promotes cardiac tissue assembly. Tissue Eng.13(9), 2185–2193 (2007).
   PubMedGoogle Scholar
• Caspi O, Lesman A, Basevitch Y et al. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ. Res.100(2), 263–272 (2007).
   PubMed Web of Science ®Google Scholar
• Shepherd BR, Hoying JB, Williams SK. Microvascular transplantation after acute myocardial infarction. Tissue Eng.13(12), 2871–2879 (2007).
   PubMedGoogle Scholar
• Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng.10(3–4), 403–409 (2004).
   PubMedGoogle Scholar
• Christman KL, Vardanian AJ, Fang Q et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J. Am. Coll. Cardiol.44(3), 654–660 (2004).
   PubMed Web of Science ®Google Scholar
• Kofidis T, de Bruin JL, Hoyt G et al. Injectable bioartificial myocardial tissue for large-scale intramural cell transfer and functional recovery of injured heart muscle. J. Thorac. Cardiovasc. Surg.128(4), 571–578 (2004).
   PubMed Web of Science ®Google Scholar
• Kofidis T, Lebl DR, Martinez EC et al. Novel Injectable Bioartificial Tissue Facilitates Targeted, Less Invasive, Large-Scale Tissue Restoration on the Beating Heart After Myocardial Injury. Circulation112(9 Suppl.), I-173–I-177 (2005).
   Google Scholar
• Kofidis T, de Bruin JL, Hoyt G et al. Myocardial restoration with embryonic stem cell bioartificial tissue transplantation. J. Heart Lung Transplant.24(6), 737–744 (2005).
   PubMed Web of Science ®Google Scholar
• Cho SW, Kim IK, Bhang SH et al. Combined therapy with human cord blood cell transplantation and basic fibroblast growth factor delivery for treatment of myocardial infarction. Eur. J. Heart Fail.9(10), 974–985 (2007).
   PubMed Web of Science ®Google Scholar
• Dai W, Wold LE, Dow JS, Kloner RA. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J. Am. Coll. Cardiol.46(4), 714–719 (2005).
   PubMed Web of Science ®Google Scholar
• Davis ME, Motion JP, Narmoneva DA et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation111(4), 442–450 (2005).
   PubMed Web of Science ®Google Scholar
• Huang NF, Yu J, Sievers R, Li S, Lee RJ. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng.11(11–12), 1860–1866 (2005).
   PubMedGoogle Scholar
• Landa N, Miller L, Feinberg MS et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarct in rat. Circulation117, 1388–1396 (2008).
   PubMed Web of Science ®Google Scholar
• Wall ST, Walker JC, Healy KE, Ratcliffe MB, Guccione JM. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation114(24), 2627–2635 (2006).
   PubMed Web of Science ®Google Scholar
• Gaudette GR, Cohen IS. Cardiac regeneration: materials can improve the passive properties of myocardium, but cell therapy must do more. Circulation114(24), 2575–2577 (2006).
   PubMed Web of Science ®Google Scholar
• Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc. Pathol.12(6), 295–310 (2003).
   PubMed Web of Science ®Google Scholar
• Segers VF, Lee RT. Local delivery of proteins and the use of self-assembling peptides. Drug Discov. Today12(13–14), 561–568 (2007).
   PubMed Web of Science ®Google Scholar
• Hsieh PCH, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J. Clin. Invest.116, 237–248 (2006).
   PubMed Web of Science ®Google Scholar
• Hsieh PCH, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation,114, 637–644 (2006).
   PubMed Web of Science ®Google Scholar
• Segers VF, Tokunou T, Higgins LJ et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation116(15), 1683–1692 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang G, Nakamura Y, Wang X et al. Controlled release of stromal cell-derived factor-1 α in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng.13(8), 2063–2071 (2007).
   PubMedGoogle Scholar
• Hao X, Silva EA, Mansson-Broberg A et al. Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res.75(1), 178–185 (2007).
   PubMed Web of Science ®Google Scholar
• Iwakura A, Fujita M, Kataoka K et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels18(2), 93–99 (2003).
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun L, Huan Y, Zhao H, Deng J. Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: analysis with dobutamine cardiovascular magnetic resonance tagging. Eur. J. Cardiothorac. Surg.30(1), 103–107 (2006).
   PubMed Web of Science ®Google Scholar
• Shao ZQ, Takaji K, Katayama Y et al. Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodeling in a rat infarct model. Circ. J.70(4), 471–477 (2006).
   PubMed Web of Science ®Google Scholar
• Fujita M, Ishihara M, Morimoto Y et al. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growthfactor-2 in a rabbit model of chronic myocardial infarction. J. Surg. Res.126, 27–33 (2005).
   PubMed Web of Science ®Google Scholar
• Davis ME, Hsieh PC, Takahashi T et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl Acad. Sci. USA103(21), 8155–8160 (2006).
   PubMed Web of Science ®Google Scholar
• Tambara K, Premaratne GU, Sakaguchi G et al. Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. Circulation112(9 Suppl.), I129–I134 (2005).
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell114(6), 763–776 (2003).
   PubMed Web of Science ®Google Scholar
• van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol.46(1), 125–133 (2005).
   PubMed Web of Science ®Google Scholar
• Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest.112(7), 999–1007 (2003).
   PubMed Web of Science ®Google Scholar
• Torella D, Rota M, Nurzinska D et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res.94, 514–524 (2004).
   PubMed Web of Science ®Google Scholar
• Conti E, Carrozza C, Capoluongo E et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation110, 2260–2265 (2004).
   PubMed Web of Science ®Google Scholar
• Liao S, Porter D, Scott A et al. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. J. Mol. Cell. Cardiol.42(1), 106–120 (2007).
   PubMed Web of Science ®Google Scholar
• Bougioukas I, Didilis V, Ypsilantis P et al. Intramyocardial injection of low-dose basic fibroblast growth factor or vascular endothelial growth factor induces angiogenesis in the infarcted rabbit myocardium. Cardiovasc. Pathol.16(2), 63–68 (2007).
   PubMed Web of Science ®Google Scholar
• Harada M, Qin Y, Takano H et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak–Stat pathway in cardiomyocytes. Nat. Med.11(3), 305–311 (2005).
   PubMed Web of Science ®Google Scholar
• Takano H, Ueda K, Hasegawa H, Komuro I. G-CSF therapy for acute myocardial infarction. Trends Pharmacol. Sci.28(10), 512–517 (2007).
   PubMed Web of Science ®Google Scholar
• Jayasankar V, Woo YJ, Bish LT et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation108(Suppl. 1), II230–II236 (2003).
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd. Periostin and myocardial repair, regeneration, and recovery. N. Engl. J. Med.357(15), 1552–1554 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn B, del Monte F, Hajjar RJ et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med.13(8), 962–969 (2007).
   PubMed Web of Science ®Google Scholar
• Hiasa K, Ishibashi M, Ohtani K et al. Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation109(20), 2454–2461 (2004).
   PubMed Web of Science ®Google Scholar
• Hu X, Dai S, Wu WJ et al. Stromal cell derived factor-1 α confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 α CXCR4 axis. Circulation116(6), 654–663 (2007).
   PubMed Web of Science ®Google Scholar
• Bock-Marquette I, Saxena A, White MD, Michael DiMaio J, Srivastava D. Thymosin [β]4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature432(7016), 466–472 (2004).
   PubMed Web of Science ®Google Scholar
• Smart N, Risebro CA, Melville AAet al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature445(7124), 177–182 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrarini M, Arsic N, Recchia FA et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ. Res.98(7), 954–961 (2006).
   PubMed Web of Science ®Google Scholar
• Poh K-K. Gene and cell therapy for chronic ischaemic heart disease. Expert Opin. Biol. Ther.7(1), 5–15 (2007).
   PubMed Web of Science ®Google Scholar